Alt Text
Office of Neuroscience Research > WUSTL Neuroscience News > NIH Weekly Funding Opportunities, Notices: April 6, 2018

NIH Weekly Funding Opportunities, Notices: April 6, 2018



Notices
Requests for Applications

     

  • Impact of Initial Influenza Exposure on Immunity in Infants (U01 Clinical Trial Not Allowed)
    (RFA-AI-18-010)
    National Institute of Allergy and Infectious Diseases
    Application Receipt Date(s): July 2, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)
    (RFA-AR-19-006)
    National Institute of Arthritis and Musculoskeletal and Skin Diseases
    Application Receipt Date(s): August 7, 2018; December 4, 2018; April 2, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • Mechanistic Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)
    (RFA-AR-19-007)
    National Institute of Arthritis and Musculoskeletal and Skin Diseases
    Application Receipt Date(s): August 7, 2018; December 4, 2018; April 2, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • Revision Applications to National Cancer Institute (NCI) Supported R01 Awards to Include Research on the NCIs Provocative Questions (R01 Clinical Trial Optional)
    (RFA-CA-18-021)
    National Cancer Institute
    Application Receipt Date(s): June 29, 2018, October 30, 2018), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • Revision Applications to National Cancer Institute (NCI) supported U01 Awards to Include Research on the NCIs Provocative Questions (U01 Clinical Trial Optional)
    (RFA-CA-18-022)
    National Cancer Institute
    Application Receipt Date(s): June 29, 2018, October 30, 2018), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • Revision Applications to National Cancer Institute (NCI)-supported P01 Awards to Include Research on the NCIs Provocative Questions (P01 Clinical Trial Optional)
    (RFA-CA-18-023)
    National Cancer Institute
    Application Receipt Date(s): June 29, 2018; October 30, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • Revision Applications to National Cancer Institute (NCI)-supported P50 Awards to Include Research on the NCIs Provocative Questions (P50 Clinical Trial Optional)
    (RFA-CA-18-024)
    National Cancer Institute
    Application Receipt Date(s): June 29, 2018; October 30, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity. 

     

  • Mechanisms Underlying the Contribution of Type 1 Diabetes Disease-associated Variants (R01 Clinical Trial Not Allowed)
    (RFA-DK-18-005)
    National Institute of Diabetes and Digestive and Kidney Diseases
    National Institute of Allergy and Infectious Diseases
    Application Receipt Date(s): December 6, 2018 , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • Limited Competition: Building Infrastructure Leading to Diversity (BUILD) Initiative Phase II (U54 Clinical Trial Not Allowed)
    (RFA-RM-18-006)
    Office of Strategic Coordination (Common Fund)
    Application Receipt Date(s): June 11, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • Cutting Edge Informatics Tools for Illuminating the Druggable Genome (U01 Clinical Trial Not Allowed)
    (RFA-RM-18-011)
    Office of Strategic Coordination (Common Fund)
    Application Receipt Date(s): July 9, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.No late applications will be accepted for this Funding Opportunity Announcement. 
Program Announcements

     

  • Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R01 Clinical Trial Optional).
    (PA-18-738)
    National Cancer Institute
    National Institute on Aging
    National Institute of Dental and Craniofacial Research
    National Institute of Nursing Research
    Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. 

     

  • Age-related Microbiota Changes and their Implications in Chronic Disease Prevention, Treatment and Progression (R21 Clinical Trial Optional).
    (PA-18-739)
    National Cancer Institute
    National Institute on Aging
    National Institute of Dental and Craniofacial Research
    National Institute of Nursing Research
    Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. 

     

  • Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21 Clinical Trial Not Allowed)
    (PA-18-741)
    National Institute of Diabetes and Digestive and Kidney Diseases
    Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • Investigator-Initiated Genomic Medicine Research (R01 Clinical Trial Optional)
    (PAR-18-735)
    National Human Genome Research Institute
    Application Receipt Date(s): June 20, 2018; October 19, 2018; June 20, 2019; October 21, 2019; June 19, 2020; October 20, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • Investigator-Initiated Genomic Medicine Research (R21 Clinical Trial Optional)
    (PAR-18-736)
    National Human Genome Research Institute
    Application Receipt Date(s): June 20, 2018; October 19, 2018; June 20, 2019; October 21, 2019; June 19, 2020; October 20, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P50 Clinical Trial Optional)
    (PAR-18-737)
    National Institute of Mental Health
    Application Receipt Date(s): June 22, 2018; May 24, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. No late applications will be accepted for this Funding Opportunity Announcement. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional)
    (PAR-18-740)
    National Institutes of Health
    National Cancer Institute
    National Eye Institute
    National Heart, Lung, and Blood Institute
    National Institute on Aging
    National Institute of Allergy and Infectious Diseases
    National Institute of Arthritis and Musculoskeletal and Skin Diseases
    Eunice Kennedy Shriver National Institute of Child Health and Human Development 
    National Institute on Drug Abuse
    National Institute of Dental and Craniofacial Research
    National Institute of Diabetes and Digestive and Kidney Diseases
    National Institute of Environmental Health Sciences
    National Institute of Mental Health
    National Institute on Minority Health and Health Disparities 
    National Institute of Neurological Disorders and Stroke
    National Institute of Nursing Research
    Application Receipt Date(s): August 31, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. 

     

  • Exploring Epigenomic or Non-Coding RNA Regulation in the Development, Maintenance, or Treatment of Chronic Pain (R61/R33 Clinical Trial Optional)
    (PAR-18-742)
    National Institute on Drug Abuse
    National Center for Complementary and Integrative Health
    Application Receipt Date(s): July 17, 2018, November 13, 2018 February 11, 2019, July 17, 2019, November 13, 2019, February 11, 2020, July 17, 2020, November 13, 2020, February 11, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • Pilot and Feasibility Clinical Research Grants in Urologic Disorders (R21 Clinical Trial Optional)
    (PAR-18-743)
    National Institute of Diabetes and Digestive and Kidney Diseases
    Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • Pilot and Feasibility Clinical Research Grants in Kidney Diseases (R21 Clinical Trial Optional)
    (PAR-18-744)
    National Institute of Diabetes and Digestive and Kidney Diseases
    Application Receipt Date(s): Standard dates apply), by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. 

     

  • NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)
    (PAR-18-746)
    National Institute on Drug Abuse
    Application Receipt Date(s): June 11, 2018; June 11, 2019; June 11, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.